Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: A post hoc analysis

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 13, Issue 4, 2011, Pages 4-

  Demyttenaere, Koen ^a   Reines, Elin Heldbo ^c   Lönn, Sara Larsson ^c   Lader, Malcolm ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; POST HOC ANALYSIS; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

EID: 80053076280     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.10m01080     Document Type: Article

References (31)

1. Demyttenaere K, Enzlin P, Dewé W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001;62(suppl 22):30-33. PubMed
2. Demyttenaere K, Enzlin P, Dewé W, et al. Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. J Clin Psychiatry. 2001;62(suppl 22):34-37. PubMed
3. von Knorring L, Akerblad AC, Bengtsson F, et al. Cost of depression: effect of adherence and treatment response. Eur Psychiatry. 2006;21(6):349-354. PubMed doi:10.1016/j.eurpsy.2006.04.005
4. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55(12):1128-1132. PubMed doi:10.1001/archpsyc.55.12.1128
5. Cramer J, Rosenheck R, Kirk G, et al; VA Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health. 2003;6(5):566-573. PubMed doi:10.1046/j.1524-4733.2003.65269.x
6. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47. doi: 10.1111/j.1524-4733.2007.00213.x PubMed
7. Bollini P, Pampallona S, Kupelnick B, et al. Improving compliance in depression: a systematic review of narrative reviews. J Clin Pharm Ther. 2006;31(3):253-260. PubMed doi:10.1111/j.1365-2710.2006.00733.x
8. Aikens JE, Nease DE Jr, Nau DP, et al. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med. 2005;3(1):23-30. PubMed doi:10.1370/afm.238
9. Russell J, Kazantzis N. Medication beliefs and adherence to antidepressants in primary care. N Z Med J. 2008;121(1286):14-20. PubMed
10. Angermeyer MC, Matschinger H. Public attitude towards psychiatric treatment. Acta Psychiatr Scand. 1996;94(5):326-336. PubMed doi:10.1111/j.1600-0447.1996.tb09868.x
11. Benkert O, Graf-Morgenstern M, Hillert A, et al. Public opinion on psychotropic drugs: an analysis of the factors influencing acceptance or rejection. J Nerv Ment Dis. 1997;185(3):151-158. PubMed doi:10.1097/00005053-199703000-00004
12. Verbeek-Heida PM, Mathot EF. Better safe than sorry-why patients prefer to stop using selective serotonin reuptake inhibitor (SSRI) antidepressants but are afraid to do so: results of a qualitative study. Chronic Illn. 2006;2(2):133-142. PubMed
13. Horne RE. Treatment perception and self-regulation. In: Cameron LD, Leventhal H, eds. The Self-Regulation of Health and Illness Behaviour. London, UK: Routledge; 2003:138-153.
14. Priest RG, Vize C, Roberts A, et al. Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. BMJ. 1996;313(7061):858-859. PubMed
15. Demyttenaere K, Bruffaerts R, Albert A, et al. Development of an antidepressant compliance questionnaire. Acta Psychiatr Scand. 2004;110(3):201-207. PubMed doi:10.1111/j.1600-0447.2004.00350.x
16. Aikens JE, Nease DE Jr, Klinkman MS. Explaining patients' beliefs about the necessity and harmfulness of antidepressants. Ann Fam Med. 2008;6(1):23-29. PubMed doi:10.1370/afm.759
17. Brown C, Battista DR, Bruehlman R, et al. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care. 2005;43(12):1203-1207. PubMed doi:10.1097/01.mlr.0000185733.30697.f6
18. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326. PubMed
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. PubMed
20. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63(4):331-336. PubMed
21. Rapaport MH, Bos A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry. 2004;65(1):44-49.
22. Kasper S, Ninan P, Ventura D, et al. Escitalopram in the treatment of severe depression. Eur Psychiatry. 2005;20(suppl 1):S143. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_SCT-MD-26_final.pdf. Accessed December 14, 2009.
23. Alexopoulos GS, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Neuropsychopharmacology. 2004;29(suppl):S87. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_SCT-MD-27_final.pdf. Accessed December 14, 2009.
24. Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004;65(9):1190-1196. PubMed doi:10.4088/JCP.v65n0906
25. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig. 2007;27(7):481-492. PubMed doi:10.2165/00044011-200727070-00005
26. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45. PubMed doi:10.1371/journal.pmed.0050045
27. Benedetti F, Vighetti S, Ricco C, et al. Pain threshold and tolerance in Alzheimer's disease. Pain. 1999;80(1-2):377-382. PubMed doi:10.1016/S0304-3959(98)00228-0
28. Wampold BE, Mondin G, Moody M, et al. A meta-analysis of outcome studies comparing bona fide psychotherapies: empirically, 'all must have prizes.' Psychol Bull. 1997;122(3):203-215. doi:10.1037/0033-2909.122.3.203
29. Lambert MJ. "Early response in psychotherapy: further evidence for the importance of common factors rather than "placebo effects. J Clin Psychol. 2005;61(7):855-869. PubMed doi:10.1002/jclp.20130
30. Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: metaanalysis. Br J Psychiatry. 2007;190(4):287-292. PubMed doi:10.1192/bjp.bp.106.028555
31. Feltner D, Hill C, Lenderking W, et al. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial. J Psychiatr Res. 2009;43(15):1224-1230. PubMed doi:10.1016/j.jpsychires.2009.04.001